|
|
Article: Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer.
- Article from:
- PR Newswire
- Article date:
- February 28, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
GRAND RAPIDS, Mich., Feb. 28 /PRNewswire/ -- The Center for Molecular Medicine (CMM) today announced it is one of the first laboratories in the nation to offer a new, FDA-approved test that will aid in the treatment of metastatic prostate cancer.
The CMM (http://www.cmmdx.org/) is offering the CellSearch(TM) System from Veridex (http://www.veridex.com/) to physicians as a vital new tool in managing patients with metastatic prostate cancer (MPC). The CMM made CellSearch testing services available to physicians last year to help inform treatment of metastatic breast and colorectal cancer.
"This newest addition to our cutting-edge menu of diagnostic ...